Value of Ki67 in breast cancer: The debate is still open

The Lancet Oncology

Volumn 11, Issue 5, 2010, Pages 414-415

  Colozza, Mariantonietta ^a   Sidoni, Angelo ^b   Piccart Gebhart, Martine ^c  

^a S MARIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ANALYTIC METHOD; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN RETRIEVAL; BREAST CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PH; PRIORITY JOURNAL; TISSUE PREPARATION; BIOSYNTHESIS; BREAST TUMOR; FEMALE; METABOLISM; NOTE; PREDICTION AND FORECASTING; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952295013     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70089-9     Document Type: Letter

References (7)

1. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11:174-183.
2. Colozza M, Azambuja E, Cardoso F, et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005, 16:1723-1739.
3. Azambuja E, Cardoso F, De Castro G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer 2007, 96:1504-1513.
4. Hayes DF, Bast RC, Desch CE, et al. Tumor Marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88:1456-1466.
5. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN Standardizing slide-based assays in breast cancer: Hormone receptors, HER2 and sentinel lymphnodes. Clin Cancer Res 2007, 13:20831-20835.
6. Goldhhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
7. Sotiriou C, Piccart M Taking gene expression profiling to the clinic: when will molecular signature become relevant to patient care?. Nat Rev Cancer 2007, 7:545-553.